DEXTENZA

Micro-cap biotech Ocular Therapeutix Inc (NASDAQ: OCUL) announced Friday that it received FDA approval for an expanded indication for its eye pain drug. What You Need to Know Ocular said the FDA approved its sNDA to expand the usage of Dextenza to include the treatment of ocular...

Despite a more than 20 percent plunge in Ocular Therapeutix Inc (NASDAQ: OCUL)'s stock Wednesday morning, analysts at Cantor Fitzgerald continue to see tremendous upside in the stock. Cantor Fitzgerald's Elemer Piros maintains an Overweight rating on Ocular's stock but with a price...

Shares of Ocular Therapeutix Inc (NASDAQ: OCUL) were trading lower by more than 30 percent heading into Wednesday's open after the biopharmaceutical company confirmed a major setback for its eye drug Dextenza, a therapy used for the treatment of ocular pain following ophthalmic surgery. Ocular...

June was event-filled as far as the PDUFA calendar was concerned. The month ushered in good tidings for the biotech sector, as most applications for approval pending before the FDA were favorably viewed. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has been up 11.70 percent thus...

Ocular Therapeutix Inc (NASDAQ: OCUL) shares sunk nearly 16 percent following a first-quarter earnings miss Friday. Despite the shares' current weakness, Cantor Fitzgerald reiterated its Overweight rating on the company with a $35 price target, well above Friday's $8. Analyst's Take On Earnings,...